Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）
- Conditions
- Infective Endocarditis
- Interventions
- Other: Observational; No Interventions were given.
- Registration Number
- NCT05965362
- Brief Summary
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
- Detailed Description
Infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. At present, the clinical diagnosis of IE is mainly based on a combination of typical symptoms, imaging and blood culture, etc. Finding more sensitive means and more accurate indicators for early detection of IE flora distribution characteristics is of great significance for the prevention and targeted treatment of IE. Therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2000
- Patients with clinically confirmed infective endocarditis
- Patients refuse to sign informed consent form
- Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Infective endocarditis group Observational; No Interventions were given. Patients diagnosed with infective endocarditis.
- Primary Outcome Measures
Name Time Method Change in the incidence of MACCE 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.
- Secondary Outcome Measures
Name Time Method Change in the incidence of all-cause death 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. All-cause death, diagnosed by clinical doctors, will be assessed from medical records.
Change in the incidence of myocardial infarction 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. Myocardial infarction, diagnosed by clinical doctors, will be assessed from medical records.
Change in the incidence of stroke 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. Stroke, diagnosed by clinical doctors, will be assessed from medical records.
Incidence of adverse thrombus complications 5 years after the enrollment. Adverse thrombus complications including systemic embolism, infected aneurysm, splenic abscess, etc.
Change in the incidence of infection recurrence 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. Diagnosis of infective endocarditis by clinical guidelines, which will be assessed from medical records.
Change in the incidence of vessel revascularization 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. Vessel revascularization, diagnosed by clinical doctors, will be assessed from medical records.
Trial Locations
- Locations (1)
First Affiliated Hospital of Xian Jiantong University
🇨🇳Xi'an, Shaanxi, China